United Therapeutics CEO executes 10b5‑1 trades, options exercised
Rhea-AI Filing Summary
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO. On 11/10/2025 and 11/11/2025, the reporting person exercised 8,000 stock options at an exercise price of $120.26 per share and sold 8,000 shares in open-market transactions.
Sales on 11/10/2025 included 3,500 shares at a weighted average price of $448.2675 (trades ranged from $448.00 to $448.53) and 500 shares at $449.22. Sales on 11/11/2025 included 1,097 shares at a weighted average price of $450.6427 (range $450.18–$451.06), 1,634 shares at $451.8664 (range $451.23–$452.09), and 1,269 shares at $452.7807 (range $452.305–$453.25).
The transactions were made under a pre-arranged Rule 10b5‑1 plan entered on May 2, 2025, which continues until the earlier of the tranche’s 294,000 expiring options being exhausted (expire March 15, 2026) or December 31, 2025. Following the transactions, directly held common stock was 130 shares, with additional indirect holdings of 166 (by spouse) and trust holdings of 324,518, 258,117, 45,596, and 15,962 shares. Remaining options beneficially owned were 106,000.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,097 | $450.6427 | $494K |
| Sale | Common Stock | 1,634 | $451.8664 | $738K |
| Sale | Common Stock | 1,269 | $452.7807 | $575K |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 3,500 | $448.2675 | $1.57M |
| Sale | Common Stock | 500 | $449.22 | $225K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $448.00 to $448.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $450.18 to $451.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $451.23 to $452.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $452.305 to $453.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
